The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | The addition of elotuzumab to backbone treatment regimens for myeloma: key takeaways
Bruno Costa, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the use of elotuzumab, a monoclonal antibody targeting SLAMF7, for treating relapsed/refractory (R/R) multiple myeloma (MM). Dr Costa conducted a meta-analysis of over 2,700 patients, which showed that the addition of elotuzumab to backbone treatment regimens improves progression-free survival (PFS), overall survival (OS), and response rates. However, elotuzumab does not benefit newly diagnosed patients, highlighting its role in later treatment lines. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
